PDCD1 and B-cell non-Hodgkin lymphoma: In addition, researchers analyzed samples of patients with relapsed DLBCL after CAR-T therapy and found that the LAG-3 and PD-1 expressions on tumor-infiltrating T cells and B-cell lymphoma increased after CAR-T therapy.